Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis October 13, 2025
Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases September 30, 2025
Hinge Bio Expands Leadership Team to Drive Clinical Development of GEM-DIMER™ Programs and Announces Publication in Scientific Reports September 4, 2025
Hinge Bio Raises $30 Million Series A’ Financing to Develop Next-Generation Therapies via its Proprietary GEM-DIMER Platform January 15, 2025
Hinge Bio Presents Preclinical Data from its GEM-DIMER™ Programs Targeting B Cell Depletion at the American College of Rheumatology (ACR) Convergence 2024 November 14, 2024
Hinge Bio, Inc. Chief Scientific Officer, Daniel Capon, Ph.D., to Present its GEM-DIMER™ Platform Technology at the University of Oxford, Kennedy Institute of Rheumatology’s Annual Translational Research Conference August 14, 2024
Hinge Bio Presents Preclinical Data from its GEM-DIMER Program Targeting B Cell Depletion at the American Association for Cancer Research (AACR) Annual Meeting 2024 April 8, 2024
Hinge Bio Expands Senior Management Team to Drive GEM-DIMER™ Programs to Clinical Development January 18, 2023
